After the consolidation, the new division will be called the R&D division. The purposes of the reorganization are to advance Kyowa Hakko Kirin’s ‘category-based strategy’ and enhance the productivity of its R&D activities.
Kyowa Hakko Kirin will implement the following measures in the new division:
– Integrate operations of drug discovery research, project management of development products and value creation research of launched products in each category-based R&D unit.
– Speed up R&D through close collaboration between category-based units and three core functions units corresponding to research technology platform, translational research (TR), and development operation, respectively.
– Enhancing drug discovery and preclinical research through open innovation style utilizing external opportunities.
Within the R&D Division, there will be R&D units for four therapeutic categories that will develop R&D plans and implement these plans for the enhancement of product pipeline in each category.
In addition to these category-based R&D units, three function-based units will be formed: the Research Functions unit, the TR unit, and the Development Functions unit.
Besides the above mentioned units, there will also be the R&D Planning Department, the Open Innovation Department, Fuji Research Park and Tokyo Research Park. Please refer to the organizational chart below for more details.